^
Association details:
| Biomarker: | C3M/PRO-C3 ratio elevation |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | pegvorhyaluronidase alfa (PEGPH20) (Hyaluronidase stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa
Published date:
01/21/2021
Excerpt:
High C3M/PRO-C3 ratio was validated in Stage 2 patients by predicting a PFS benefit of PAG vs. AG (mPFS: 8.8 vs. 3.4 months, P = 0.046; HR = 0.46; 95% CI 0.21-0.98).
DOI:
10.1186/s12967-021-02701-z
Trial ID:
